Payment overview · 2025
General Payments
$378.82
14 reported records · 11 companies
Healthcare provider profile · identity verified
Fahad Alam
Allopathic & Osteopathic Physicians|Internal Medicine · LINCOLN, NE · NPI 1518457894
Verified facts
What the public records show
CMS Open Payments records show Fahad Alam received $378.82 in general payments during 2025 across 14 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.85 | 29.3% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $77.45 | 20.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.80 | 14.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.41 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.57 | 4.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.14 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.31 | 4.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.97 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 3.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.17 | 3.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.53 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.82 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $110.85 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $77.45 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $77.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 76 |
| Losartan Potassium | Losartan Potassium | 255 | 70 |
| Gabapentin | Gabapentin | 224 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 59 |
| Metformin Hcl | Metformin Hcl | 189 | 51 |
| Potassium Chloride | Potassium Chloride | 188 | 51 |
| Alprazolam | Alprazolam | 166 | 41 |
| Tramadol Hcl | Tramadol Hcl | 164 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 43 |
| Montelukast Sodium | Montelukast Sodium | 141 | 37 |
| Lisinopril | Lisinopril | 137 | 43 |
| Furosemide | Furosemide | 134 | 39 |
| Simvastatin | Simvastatin | 126 | 36 |
| Omeprazole | Omeprazole | 121 | 34 |
| Prednisone | Prednisone | 113 | 83 |
| Warfarin Sodium | Warfarin Sodium | 110 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 30 |
| Carvedilol | Carvedilol | 96 | 27 |
| Trazodone Hcl | Trazodone Hcl | 96 | 28 |
| Ezetimibe | Ezetimibe | 89 | 28 |
| Allopurinol | Allopurinol | 88 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 23 |
| Azithromycin | Azithromycin | 84 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 22 |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 28 |
| Sertraline Hcl | Sertraline Hcl | 70 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 18 |
| Clonazepam | Clonazepam | 61 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 28 |
| Spironolactone | Spironolactone | 57 | suppressed |
| Eliquis | Apixaban | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 40 |
| Glimepiride | Glimepiride | 50 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Meloxicam | Meloxicam | 43 | 16 |
| Famotidine | Famotidine | 42 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 14 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 35 |
| Lorazepam | Lorazepam | 39 | 11 |
| Pregabalin | Pregabalin | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 12 |
| Estradiol | Estradiol | 37 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Indapamide | Indapamide | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Primidone | Primidone | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | 11 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Misoprostol | Misoprostol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.82 · 14 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, JARDIANCE, Kerendia, NURTEC ODT, OPSUMIT, Ozempic, REXULTI, Rybelsus, TZIELD, UPTRAVI, WATCHMAN Access System, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error